The historical rank and industry rank for Tandem Diabetes Care's Pretax Margin % or its related term are showing as below:
LTS:0M0F'
s Pretax Margin % Range Over the Past 10 Years
Min: -99.07 Med: -15.67 Max: 2.26
Current: -9.54
LTS:0M0F's Pretax Margin % is ranked worse than 62.79% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs LTS:0M0F: -9.54
Tandem Diabetes Care (LTS:0M0F) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Tandem Diabetes Care Pretax Margin % Related Terms
Tandem Diabetes Care Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M0F vs CNMD, AORT, LMRI: Pretax Margin % Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (LTS:0M0F) has a Pretax Margin % of -8.04% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tandem Diabetes Care and its competitors. According to the industry distribution chart, Tandem Diabetes Care ranks #513 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 62.8%.
Is Tandem Diabetes Care's Pretax Margin % too high?
Tandem Diabetes Care's current Pretax Margin % is -8.04%. Based on the distribution chart, Tandem Diabetes Care ranks #513 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Pretax Margin % compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #513 out of 817 companies for Pretax Margin %. This places Tandem Diabetes Care in the lower half of its industry. The industry median Pretax Margin % is 2.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.40, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current Pretax Margin % is -8.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.16, compared to a current price of $15.63 — trading 46.4% below its estimated fair value. The current Pretax Margin % is -8.04%. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Pretax Margin % is -8.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $15.63 is trading 46.4% below its estimated GF Value™ of $29.16.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
Pretax Margin %: -8.04%
GF Value™: $29.16 vs. price of $15.63 (46.4% below fair value)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score
Get the complete analysis for LTS:0M0F
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
